ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

In Brief: WHI Revises Protocol After Study Finds High Rate Of Endometrial Hyperplasia

January 27, 1995

CTEP-Approved Trials For the Month of June

June 28, 2013

Sondik Named Acting DCPC Deputy Director Sinks Leaving at End Of Month; Edwards Costlow Acting Ads

July 21, 1989

In Brief: Jane Henney Sworn In As FDA Commissioner; Six Centers Retain Comprehensive Status

December 18, 1998

Also C-Change new name for National Dialogue on Cancer.

January 16, 2004

Wendy Will Case Found Invites Applications For Small Grants

April 5, 1991